Search term | |
1. Immunotherapy/ | |
2. immunotherap*.ti,ab. | |
3. immuno therap*.ti,ab. | |
4. immuno-oncology.ti,ab. | |
5. immunooncology.ti,ab. | |
6. immuno oncology.ti,ab. | |
7. immuno-therap*.ti,ab. | |
8. chemoimmunotherap*.ti,ab. | |
9. chemo-immunotherap*.ti,ab | |
10. checkpoint inhibitor*.ti,ab. | |
11. check-point inhibitor*.ti,ab. | |
12. check point inhibitor*.ti,ab. | |
13. check-point block*.ti,ab. | |
14. checkpoint block*.ti,ab. | |
15. check point block*.ti,ab. | |
16. check-point therap*.ti,ab. | |
17. checkpoint therap*.ti,ab. | |
18. check point therap*.ti,ab. | |
19. pd-l1.ti,ab. | |
20. pd-1.ti,ab. | |
21. ctla-4.ti,ab. | |
22. exp CTLA-4 Antigen/ | |
23. Cytotoxic T-Lymphocyte Associated Antigen 4.ti,ab. | |
24. Cytotoxic T-Lymphocyte Antigen 4.ti,ab. | |
25. exp Programmed cell death 1 receptor/ | |
26. Programmed cell death 1 receptor.ti,ab. | |
27. Programmed cell death 1 protein.ti,ab. | |
28. Pd 1 protein.ti,ab. | |
29. PDCD1 protein.ti,ab | |
30. CD279 antigen.ti,ab. | |
31. nivolumab.ti,ab. | |
32. Opdivo.ti,ab. | |
33. pembrolizumab.ti,ab. | |
34. Keytruda.ti,ab. | |
35. durvalumab.ti,ab. | |
36. Imfinzi.ti,ab. | |
37. tremelimumab.ti,ab. | |
38. Exp ipilimumab/ | |
39. Yervoy.ti,ab. | |
40. atezolizumab.ti,ab. | |
41. Tecentriq.ti,ab. | |
42. avelumab.ti,ab. | |
43. Bavencio.ti,ab. | |
44. Economics/ | |
45. exp Costs and Cost Analysis/ | |
46. Economics, Medical/ | |
47. Economics, Nursing/ | |
48. Economics, Pharmaceutical/ | |
49. exp Economics, Hospital/ | |
50. exp “Fees and Charges”/ | |
51. exp Budgets/ | |
52. economic*.ti,ab. | |
53. cost*.ti,ab. | |
54. pric*.ti,ab. | |
55. fees.ti,ab. | |
56. pharmacoeconomic.ti,ab. | |
57. pharmaco-economic.ti,ab. | |
58. expendit*.ti,ab. | |
59. (value adj2 mone*).ti,ab. | |
60. exp models, economic/ | |
61. exp Neoplasms/ | |
62. cancer*.ti,ab. | |
63. neoplas*.ti,ab. | |
64. tumor.ti,ab. | |
65. tumor.ti,ab. | |
66. malignan*.ti,ab. | |
67. or/1–43 | |
68. or/44–60 | |
69. or/61–66 | |
70. 67 and 68 and 69 |